Expert Interview
Discussing the data from Sana Bio's first-in-human study transplanting UP421 in patients with type-1 diabetes - Islet Cell Transplantation Without Immunosuppression
Ticker(s): SANA- Board Certified Endocrinologist fellowship trained at University of California San Francisco.
- Manages ~400 patients annually for weight loss and obesity.
- Practicing in endocrinology for over 20 years.
On a scale of 1 to 10, how excited are you for this islet cell therapy?
Added By: max_adminWhat percentage of your patients would consider cell therapy in contrast to current standard of care?
Added By: max_adminHow do you define the risk factors for developing type 1 diabetes, and how does the management of type 1 diabetes differ from type 2 in terms of treatment approaches, devices like insulin pumps, and overall patient outcomes?
Added By: slingshot_insightsWhat are your thoughts on islet cell transplantation as a treatment for type 1 diabetes, including its current limitations due to immunosuppression? If a scalable, immunosuppression-free treatment like UP421 is successful, how transformative would it be for patient care?
Added By: slingshot_insightsBased on Sana’s first-in-human trial data, how do you interpret the significance of the reported C-peptide levels, immune response findings, and ischemia time of donor islet cells? Do these results provide a compelling proof of concept?
Added By: slingshot_insightsIf UP421 and similar approaches using pluripotent stem cells succeed in larger trials, what impact could they have on the future of diabetes treatment, transplant workflows, and patient demand for the therapy?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
